Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback